Alterome Therapeutics
PrivateLast Round
Series B
Apr 3, 2024
Total Funding Raised
$231M
Company Overview
Alterome Therapeutics is a biopharmaceutical company that develops alteration-specific targeted therapies for the treatment of cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Alterome Therapeutics Comparables
Compare Alterome Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Terremoto Biosciences | 90% | |
| Atavistik Bio | 89% | |
| Delphia Therapeutics | 79% | |
Alterome Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Apr 3, 2024 | ||||
| Series A Extension | Nov 2, 2022 | ||||
| Series A | Jan 19, 2022 |
Key People
Founding team and executive leadership
Alterome Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Boxer Capital | Series A Extension, Series B, Series A |
| Digitalis Ventures | Series B |
| Vida Ventures | Series A Extension, Series B, Series A |
| Blue Owl Capital | Series B |
| OrbiMed | Series B, Series A Extension, Series A |
| Invus Opportunities | Series B |
| Canaan Partners | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 2, 2026
Leonardo Faoro appointed as new Chief Medical Officer.
- Apr 3, 2024
$132M round led by Goldman Sachs Alternatives.
Alterome Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Alterome Therapeutics's valuation, stock price, and market status.